Page last updated: 2024-08-21

vancomycin and telavancin

vancomycin has been researched along with telavancin in 101 studies

Research

Studies (101)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	35 (34.65)	29.6817
2010's	62 (61.39)	24.3611
2020's	4 (3.96)	2.80

Authors

Authors	Studies
Almela, M; Armero, Y; de-Lazzari, E; del Rio, A; García-de-la-Mària, C; Gatell, JM; Jiménez-de-Anta, MT; Marco, F; Mestres, CA; Miró, JM; Moreno, A; Soy, D	1
Jansen, WT; Milatovic, D; Verel, A; Verhoef, J	1
Cars, O; Löwdin, E; Odenholt, I	1
Clouse, FL; Hovde, LB; Rotschafer, JC	1
Barriere, SL; Benton, BM; Goldberg, MR; Gotfried, MH; Kitt, MM; Krause, KM; Shaw, JP	1
Lombardo, F; Obach, RS; Waters, NJ	1
Benton, BM; Draghi, DC; Krause, KM; Pillar, C; Sahm, DF; Thornsberry, C	1
Benton, BM; Debabov, DV; Difuntorum, S; Krause, KM; Renelli, M; Wu, TX	1
Denis, O; Nguyen, HA; Struelens, MJ; Theunis, A; Tulkens, PM; Van Bambeke, F; Vergison, A	1
Darouiche, RO; Mansouri, MD; Schneidkraut, MJ	1
Leonard, SN; Rybak, MJ; Vidaillac, C	1
LaPlante, KL; Mermel, LA	1
Benton, BM; Hartouni, SR; Humphrey, PP; Janc, JW; Lunde, CS; Mammen, M	1
Bolanos, M; Finegold, SM; Molitoris, DR; Sumannen, PH	1
Janechek, MJ; Jones, RN; Mendes, RE; Moet, GJ	1
Benton, BM; Blais, J; Hill, CM; Humphrey, PP; Janc, JW; Kinana, A; Krause, KM; Lewis, SR; Mammen, M	1
Crandon, JL; Kuti, JL; Nicolau, DP	1
Benadda, S; Chau, F; Dubée, V; Fantin, B; Lefort, A	1
Akkapeddi, P; Haldar, J; Manjunath, GB; Yarlagadda, V	1
Chen, F; Gong, L; Guan, D; Huang, W; Lan, L; Li, J; Qiu, Y; Tang, F; Xiong, L; Zhang, N	1
Lonneman, M; Wetzel, C; Wu, C	1
Hegde, SS; Judice, JK; Kaniga, K; McCullough, J; Obedencio, G; Pace, J; Reyes, N; Shaw, JP; Skinner, R; Thomas, R; Vanasse, N; Wiens, T	1
Adams, SM; Bazzini, B; Christensen, BG; Fatheree, PR; Judice, JK; Karr, DE; Krause, KM; Lam, BM; Leadbetter, MR; Linsell, MS; Nodwell, MB; Pace, JL; Quast, K; Shaw, JP; Soriano, E; Trapp, SG; Villena, JD; Wu, TX	1
Van Bambeke, F	1
Barriere, SL; Cabell, CH; Chu, VH; Corey, GR; Dunbar, LM; Fowler, VG; Kitt, MM; Lau, WK; O'Riordan, WD; Pien, FD; Spencer, E; Stryjewski, ME; Vallee, M	1
Basuino, L; Chambers, HF; Madrigal, AG	1
Barriere, SL; Chu, VH; Corey, GR; Dunbar, LM; Fowler, VG; Kitt, MM; Morganroth, J; O'Riordan, WD; Stryjewski, ME; Vallée, M; Warren, BL; Young, DM	1
Benton, BM; Hegde, SS; Krause, KM; Obedencio, GP; Reyes, N; Shelton, J; Skinner, R	1
Barcia-Macay, M; Lemaire, S; Mingeot-Leclercq, MP; Tulkens, PM; Van Bambeke, F	1
Attwood, RJ; LaPlante, KL	1
Loffler, CA; Macdougall, C	1
Barriere, SL; Corey, GR; Fowler, VG; Friedland, HD; Graham, DR; Hopkins, A; Kitt, MM; Lentnek, A; O'Riordan, W; Ross, DP; Stryjewski, ME; Wilson, SE; Young, D	1
Firsov, AA; Lubenko, IY; Portnoy, YA; Smirnova, MV; Strukova, EV; Vostrov, SN; Zinner, SH	1
Barriere, SL; Kuti, JL; Laohavaleeson, S; Nicolau, DP	1
Calhoun, JH; Thomas, TS; Wirtz, ED; Yin, LY	1
Barriere, SL; Friedland, HD; Hopkins, A; Kitt, MM; O'Riordan, W; Wilson, SE	1
Difuntorum, S; Hegde, SS; Krause, KM; Skinner, R; Trumbull, J	1
Appelbaum, PC; Beachel, L; Clark, C; Dewasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA	1
Eliopoulos, GM	1
Bae, IG; Barriere, SL; Corey, GR; Fowler, VG; Genter, FC; Reilly, LF; Rude, TH; Stryjewski, ME; Tonthat, GT	1
Nailor, MD; Sobel, JD	1
Blick, SK; Lyseng-Williamson, KA	1
Citron, DM; Goldstein, EJ; Tyrrell, KL; Warren, YA	1
Axt, S; Benton, BM; Hartouni, SR; Lunde, CS; Rexer, CH	1
Wei, Y; Yu, L; Zhong, M	1
Barriere, SL; Benton, BM; Kitt, MM; Krause, KM	1
Camins, BC; Marcos, LA	1
Levy, F; Peterson, SM; Reynolds, SA; Sarubbi, FA; Shams, W; Walker, ES	1
Bowker, KE; Elliott, HC; MacGowan, AP; Noel, AR; Tomaselli, S	1
Barriere, SL	2
Jones, RN; Mendes, RE; Pfaller, MA; Rhomberg, PR; Sader, HS	1
Barriere, SL; Corey, GR; Fagon, JY; Friedland, HD; Genter, FC; Kanafani, ZA; Kitt, MM; Kollef, MH; Lalani, T; Lee, PC; Lentnek, AL; Luna, CM; Nannini, EC; Niederman, MS; Rahav, G; Rocha, MG; Rubinstein, E; Shorr, AF; Stryjewski, ME; Torres, A	1
Diagre, D; Hussain, Z; John, MA; Milburn, S; Stuart, JI; Wilson, B	1
Adam, HJ; Hoban, DJ; Karlowsky, JA; Poutanen, SM; Zhanel, GG	1
Grigoryan, IV; Leonard, SN; Szeto, YG; Zolotarev, M	1
Tarchini, G	1
Cleveland, KO; Gelfand, MS; Twilla, JD; Usery, JB	1
Cleveland, KO; Gelfand, MS; Memon, KA	1
Rybak, MJ; Steed, ME; Vidaillac, C	1
Graviss, EA; Marconescu, P; Musher, DM	1
Fallon, M; Moran, JJ; Rose, WE; Vanderloo, JP	1
LaPlante, KL; Mermel, LA; Woodmansee, S	1
Ahmed, MS; Fokina, V; Hankins, GD; Nanovskaya, T; Patrikeeva, S; Zhan, Y	1
Corey, GR; Nannini, EC; Stryjewski, ME	1
Bonilla, HF; Evans, DJ; Freedy, HR; Windisch, RM	1
Benton, BM; Lunde, CS; Song, Y; Wilkinson, BJ	1
Gemmell, CG; Lang, S; Smith, K	1
Barriere, SL; Corey, GR; Genter, FC; Lentnek, AL; Luna, CM; Magana-Aquino, M; Niederman, MS; Rubinstein, E; Stryjewski, ME; Torres, A	1
Anyanwu, A; Huprikar, S; Labombardi, V; Lee, M; Patel, G; Pinney, S; Swartz, TH	1
Cars, O; Forsberg, P; Giske, CG; Hickman, RA; Lagerbäck, P; Tängdén, T	1
Barriere, SL; Corey, GR; Hopkins, A; Kollef, MH; Rubinstein, E; Shorr, AF; Stryjewski, ME	1
Muscedere, J	1
Madaj, J; Ślusarz, R; Szulc, M	1
Coyle, E; Nesher, L; Prince, RA; Rolston, K; Shelburne, S; Wang, W	1
Barriere, SL; Corey, GR; Fowler, VG; Kitt, MM; Lentnek, A; Miró, JM; O'Riordan, W; Pullman, J; Stryjewski, ME; Tambyah, PA	1
Barriere, SL; Clark, D; Liao, S; McConeghy, KW; Rodvold, KA; Worboys, P	1
Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Sader, HS	2
Barriere, SL; Corey, GR; Pushkin, R; Stryjewski, ME; Wang, W	1
Barriere, SL; Corey, GR; Hardin, TC; Lacy, MK; Luke, DR; Nogid, B; Shorr, AF; Stryjewski, ME; Wang, W	1
Kuti, JL; Nicolau, DP; Thabit, AK	1
Al Hamal, Z; Chaftari, AM; El Zakhem, A; Gagel, A; Garoge, K; Granwehr, B; Hachem, R; Jiang, Y; Jordan, M; Mulanovich, V; Raad, I; Reitzel, R; Viola, GM; Yousif, A	1
Borgert, SJ; Klinker, KP	1
Brazeau, DA; Brown, T; Bulman, ZP; Gill, SR; Lenhard, JR; Meaney, CJ; Norgard, NB; Rybak, MJ; Tsuji, BT	1
LaPlante, KL; Luther, MK; Mermel, LA	1
Abdelhady, W; Bayer, AS; Tang, C'; Xiong, YQ	1
Barriere, SL; Corey, GR; Smart, JI; Stryjewski, ME; Wang, W	1
Nesher, L; Prince, RA; Rolston, KV; Rybak, MJ; Smith, JR; Wang, W	1
Arhin, FF; Belley, A; Moeck, G; Seguin, DL	1
Liu, Y; Wang, J	1
Corman, S; Gordon, LM; Leung, GH; Lodise, TP; McKinnell, JA; Patel, D	1
Bruss, J; Dwyer, J; Jacobs, M; Lacy, MK; Nogid, B	1
Bernstein, AT; Esther, CR; Goralski, JL; Leigh, MW; McKinzie, CJ	1
Eberl, S; Nussbaumer-Proell, A; Oesterreicher, Z; Peilensteiner, T; Zeitlinger, M	1
Blaskovich, MAT; Cooper, MA; Gong, Y; Kavanagh, A; Ramu, S	1
Burnham, CD; Lainhart, W; McMullen, AR; Shupe, A; Wallace, MA	1
Epps, KL; Epps, QJ; Young, DC; Zobell, JT	1
Chua, KY; Deshpande, P; Gibson, A; Holmes, NE; Konvinse, KC; Li, D; Mouhtouris, E; Nakkam, N; Ostrov, DA; Phillips, EJ; Trubiano, J	1
Chen, YH; Chen, YS; Cheng, SH; Hsueh, PR; Ko, WC; Lee, CM; Lee, WS; Lee, YL; Liao, CH; Lin, CY; Liu, CP; Liu, PY; Lu, MC; Lu, PL; Shao, PL; Sheng, WH; Shi, ZY; Tsai, HY; Tseng, SH; Wang, FD; Wang, LS; Wu, TS; Yen, MY	1

Reviews

9 review(s) available for vancomycin and telavancin

Article	Year
Polypharmacological drug actions of recently FDA approved antibiotics. European journal of medicinal chemistry, 2021, Jan-01, Volume: 209 Topics: Anti-Bacterial Agents; beta-Lactams; Drug Approval; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Humans; Lipoglycopeptides; Pharmaceutical Preparations; Polypharmacology; Quinolones; Small Molecule Libraries; Structure-Activity Relationship; United States; United States Food and Drug Administration	2021
Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Current opinion in pharmacology, 2004, Volume: 4, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Glycopeptides; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Teicoplanin; Vancomycin	2004
Telavancin: a novel lipoglycopeptide antimicrobial agent. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Nov-15, Volume: 64, Issue:22 Topics: Aminoglycosides; Anti-Bacterial Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Multiple, Bacterial; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Vancomycin	2007
Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. The Journal of infection, 2009, Volume: 59 Suppl 1 Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Teicoplanin; Vancomycin	2009
Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infectious disease clinics of North America, 2009, Volume: 23, Issue:4 Topics: Aminoglycosides; Anti-Bacterial Agents; Daptomycin; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Peptides, Cyclic; Teicoplanin; Vancomycin; Virginiamycin	2009
Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies. Expert review of anti-infective therapy, 2012, Volume: 10, Issue:8 Topics: Aminoglycosides; Anti-Bacterial Agents; Creatinine; Cross Infection; Drug Administration Schedule; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin	2012
Beyond Vancomycin: The Tail of the Lipoglycopeptides. Clinical therapeutics, 2015, Dec-01, Volume: 37, Issue:12 Topics: Aminoglycosides; Anti-Bacterial Agents; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Lipopeptides; Methicillin-Resistant Staphylococcus aureus; Teicoplanin; Vancomycin; Vancomycin-Resistant Enterococci	2015
A comparison of telavancin and vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections: A meta-analysis. International journal of clinical pharmacology and therapeutics, 2017, Volume: 55, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Humans; Kidney Diseases; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Treatment Outcome; Vancomycin	2017
State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics. Pediatric pulmonology, 2020, Volume: 55, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Ciprofloxacin; Clindamycin; Cystic Fibrosis; Humans; Linezolid; Lipoglycopeptides; Methicillin; Methicillin-Resistant Staphylococcus aureus; Rifampin; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin	2020

Trials

14 trial(s) available for vancomycin and telavancin

Article	Year
Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:1 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Bronchoscopy; Female; Humans; Injections, Intravenous; Lipoglycopeptides; Lung; Macrophages, Alveolar; Male; Methicillin Resistance; Microbial Sensitivity Tests; Pulmonary Surfactants; Staphylococcus aureus; Streptococcus pneumoniae; Treatment Outcome	2008
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jun-01, Volume: 40, Issue:11 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Double-Blind Method; Female; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Middle Aged; Penicillins; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin	2005
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:3 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Penicillins; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin	2006
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Jun-01, Volume: 46, Issue:11 Topics: Adult; Aminoglycosides; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Middle Aged; Skin Diseases, Infectious; Treatment Outcome; Vancomycin	2008
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. American journal of surgery, 2009, Volume: 197, Issue:6 Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Retrospective Studies; Skin Diseases, Infectious; Staphylococcal Infections; Surgical Wound Infection; Vancomycin	2009
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational tr Journal of clinical microbiology, 2009, Volume: 47, Issue:12 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; Double-Blind Method; Electrophoresis, Gel, Pulsed-Field; Exotoxins; Female; Humans; Internationality; Leukocidins; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Polymerase Chain Reaction; Prognosis; Severity of Illness Index; Staphylococcal Skin Infections; Treatment Outcome; Vancomycin	2009
In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. Diagnostic microbiology and infectious disease, 2010, Volume: 68, Issue:2 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Skin; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus; Vancomycin	2010
ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future microbiology, 2010, Volume: 5, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Female; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Treatment Outcome; Vancomycin	2010
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Jan-01, Volume: 52, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Double-Blind Method; Female; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Pneumonia, Staphylococcal; Treatment Outcome; Vancomycin	2011
The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future microbiology, 2014, Volume: 9, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Female; Humans; Lipoglycopeptides; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Treatment Outcome; Vancomycin	2014
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC infectious diseases, 2014, May-23, Volume: 14 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Catheter-Related Infections; Double-Blind Method; Female; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Penicillins; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin	2014
Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Sep-15, Volume: 61 Suppl 2 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Coinfection; Cross Infection; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospital Mortality; Humans; Lipoglycopeptides; Male; Middle Aged; Pneumonia, Ventilator-Associated; Time Factors; Treatment Outcome; Vancomycin; Young Adult	2015
Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Female; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hematologic Neoplasms; Humans; Lipoglycopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Neutropenia; Pilot Projects; Recurrence; Treatment Outcome; Vancomycin	2016
Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates. Diagnostic microbiology and infectious disease, 2017, Volume: 87, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Skin Infections; Vancomycin	2017

Other Studies

78 other study(ies) available for vancomycin and telavancin

Article	Year
Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Aminoglycosides; Animals; Anti-Infective Agents; Aortic Valve; Colony Count, Microbial; Endocarditis, Bacterial; Heart Valve Diseases; Humans; Infusion Pumps; Infusions, Intravenous; Lipoglycopeptides; Microbial Sensitivity Tests; Models, Theoretical; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Time Factors; Treatment Outcome; Vancomycin	2007
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Europe; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes; Vancomycin Resistance; Viridans Streptococci	2007
Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Aminoglycosides; Anti-Bacterial Agents; Area Under Curve; Colony Count, Microbial; Culture Media; Humans; Kinetics; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Models, Statistical; Serum; Serum Albumin; Staphylococcus aureus	2007
In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:12 Topics: Aminoglycosides; Anti-Bacterial Agents; Cefazolin; Dialysis Solutions; Lipoglycopeptides; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Peritoneal Dialysis; Staphylococcus aureus; Time Factors; Vancomycin	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Prospective Studies; Staphylococcus aureus; Streptococcus; Streptococcus pneumoniae; United States	2008
In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus; Streptococcus	2008
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:4 Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Dose-Response Relationship, Drug; Fusidic Acid; Gentamicins; Humans; Macrophages; Microbial Sensitivity Tests; Oxacillin; Phenotype; Protein Binding; Staphylococcus aureus; Thymidine	2009
Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:6 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Catheter-Related Infections; Female; Lipoglycopeptides; Rabbits; Staphylococcal Infections; Vancomycin	2009
Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7 Topics: Aminoglycosides; Gentamicins; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Rifampin; Staphylococcus aureus; Vancomycin	2009
In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Biofilms; Enterococcus faecalis; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus aureus; Staphylococcus epidermidis; Vancomycin	2009
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8 Topics: Aminoglycosides; Anti-Bacterial Agents; Cell Wall; Flow Cytometry; Lipoglycopeptides; Membrane Potentials; Methicillin Resistance; Microbial Sensitivity Tests; Microscopy, Phase-Contrast; Staphylococcus aureus; Uridine Diphosphate N-Acetylmuramic Acid; Vancomycin	2009
In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria, Anaerobic; Clostridioides difficile; Gram-Negative Bacteria; Gram-Positive Bacteria; Lipoglycopeptides; Microbial Sensitivity Tests	2009
In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Daptomycin; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Linezolid; Lipoglycopeptides; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Virginiamycin	2010
Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Blotting, Western; Carbon-Oxygen Ligases; Drug Resistance, Bacterial; Enterococcus; Gene Expression Regulation, Bacterial; Lipoglycopeptides; Operon; Teicoplanin; Vancomycin; Vancomycin Resistance	2010
Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:12 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pneumonia; Staphylococcal Infections; Vancomycin	2010
Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Daptomycin; Enterococcus faecalis; Flow Cytometry; Lipoglycopeptides; Microscopy, Confocal; Vancomycin	2011
Membrane active vancomycin analogues: a strategy to combat bacterial resistance. Journal of medicinal chemistry, 2014, Jun-12, Volume: 57, Issue:11 Topics: Animals; Bacteremia; Cell Membrane Permeability; Drug Resistance, Bacterial; Enterococcus; Female; HeLa Cells; Hemolysis; Humans; Mice; Microbial Sensitivity Tests; Neutropenia; Quaternary Ammonium Compounds; Staphylococcal Infections; Staphylococcus; Structure-Activity Relationship; Triazoles; Vancomycin	2014
Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. Journal of medicinal chemistry, 2018, 01-11, Volume: 61, Issue:1 Topics: Animals; Anti-Bacterial Agents; Cell Line; Drug Resistance, Multiple; Female; Humans; Hydrophobic and Hydrophilic Interactions; Male; Mice; Microbial Sensitivity Tests; Peptidoglycan; Staphylococcus aureus; Structure-Activity Relationship; Sugars; Vancomycin; Vancomycin-Resistant Enterococci	2018
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:8 Topics: Acetamides; Aminoglycosides; Animals; Anti-Bacterial Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Endpoint Determination; Female; Gram-Positive Bacterial Infections; Linezolid; Lipoglycopeptides; Methicillin Resistance; Mice; Muscle, Skeletal; Nafcillin; Neutropenia; Oxazolidinones; Protein Binding; Staphylococcal Infections; Subcutaneous Tissue; Vancomycin	2004
Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). The Journal of antibiotics, 2004, Volume: 57, Issue:5 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Female; Gram-Positive Bacteria; Indicators and Reagents; Injections, Intravenous; Lipoglycopeptides; Microbial Sensitivity Tests; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Teicoplanin; Tissue Distribution; Vancomycin	2004
Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:8 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Aortic Valve; Disease Models, Animal; Drug Resistance, Bacterial; Endocarditis, Bacterial; Heart Valve Diseases; Humans; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin	2005
Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:2 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteremia; Blood; Disease Models, Animal; Lipoglycopeptides; Methicillin Resistance; Mice; Spleen; Staphylococcal Infections; Staphylococcus aureus; Survival Analysis; Vancomycin	2006
Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:6 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Cell Line; Colony Count, Microbial; Dose-Response Relationship, Drug; Humans; Lipoglycopeptides; Macrophages; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Microbial Viability; Staphylococcus aureus; Time Factors; Vancomycin	2006
Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections. Expert review of anti-infective therapy, 2007, Volume: 5, Issue:6 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Clindamycin; Daptomycin; Doxycycline; Folic Acid Antagonists; Global Health; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin; Methicillin Resistance; Minocycline; Oxazolidinones; Prevalence; Staphylococcal Infections; Staphylococcus aureus; Sulfamethoxazole; Teicoplanin; Tigecycline; Trimethoprim; Vancomycin	2007
Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Area Under Curve; Colony Count, Microbial; In Vitro Techniques; Lipoglycopeptides; Microbial Sensitivity Tests; Microbial Viability; Models, Statistical; Staphylococcus aureus; Time Factors; Vancomycin	2008
Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy, 2008, Volume: 28, Issue:12 Topics: Adult; Aged; Algorithms; Aminoglycosides; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Databases, Factual; Drug Utilization Review; Female; Hospitalization; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Multicenter Studies as Topic; Skin; Staphylococcal Skin Infections; Vancomycin	2008
Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:2 Topics: Acetamides; Aminoglycosides; Animals; Anti-Bacterial Agents; Bone Marrow; Colony Count, Microbial; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Osteomyelitis; Oxazolidinones; Rabbits; Random Allocation; Staphylococcal Infections; Treatment Outcome; Vancomycin	2009
Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:4 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteremia; Blood; Colony Count, Microbial; Drug Resistance, Bacterial; Female; Glycopeptides; Lipoglycopeptides; Mice; Spleen; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin	2009
Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:10 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Enterococcus; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Point Mutation; Staphylococcus; Vancomycin; Virginiamycin	2009
Telavancin. Drugs, 2009, Volume: 69, Issue:18 Topics: Adult; Aminoglycosides; Animals; Anti-Bacterial Agents; Cross Infection; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacteria; Humans; Lipoglycopeptides; Methicillin; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxacillin; Skin Diseases, Infectious; Staphylococcal Infections; Treatment Outcome; Vancomycin	2009
Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile. Anaerobe, 2010, Volume: 16, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Humans; Lipoglycopeptides; Metronidazole; Microbial Sensitivity Tests; Prohibitins; Time Factors; Vancomycin	2010
Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Cell Division; Cell Wall; Fluorescent Antibody Technique; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microscopy, Fluorescence; Vancomycin	2010
Direct fluorescence polarization assay for the detection of glycopeptide antibiotics. Analytical chemistry, 2010, Aug-15, Volume: 82, Issue:16 Topics: Aminoglycosides; Anti-Bacterial Agents; Fluorescence Polarization; Glycopeptides; Humans; Immunoassay; Lipoglycopeptides; Oligopeptides; Protein Binding; Teicoplanin; Vancomycin	2010
Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:12 Topics: Aminoglycosides; Anti-Bacterial Agents; Endocarditis; Female; Humans; Lipoglycopeptides; Middle Aged; Pacemaker, Artificial; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin	2010
Comparative activity of telavancin and other antimicrobial agents against methicillin-resistant Staphylococcus aureus isolates collected from 1991 to 2006. Chemotherapy, 2010, Volume: 56, Issue:5 Topics: Acetamides; Aminoglycosides; Anti-Infective Agents; Daptomycin; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Minocycline; Oxazolidinones; Tigecycline; Vancomycin	2010
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:2 Topics: Aminoglycosides; Anti-Bacterial Agents; Culture Media; Enterococcus; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Biological; Staphylococcus aureus; Teicoplanin; Vancomycin	2011
Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections. Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; Drug Resistance, Bacterial; Enterococcus; Exotoxins; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Leukocidins; Lipoglycopeptides; Microbial Sensitivity Tests; Population Surveillance; Skin; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus; Staphylococcus aureus; Streptococcus; Vancomycin	2010
Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin. International journal of antimicrobial agents, 2011, Volume: 37, Issue:3 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Daptomycin; DNA, Ribosomal; Linezolid; Lipoglycopeptides; Microbial Sensitivity Tests; Micrococcal Nuclease; Minocycline; Oxacillin; Oxazolidinones; Penicillin-Binding Proteins; Polymerase Chain Reaction; Staphylococcus; Tigecycline; Vancomycin	2011
In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. Diagnostic microbiology and infectious disease, 2011, Volume: 69, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Canada; Hospitals; Humans; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Penicillin Resistance; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcal Infections; Streptococcus; Streptococcus pneumoniae; Streptococcus pyogenes; Teicoplanin; Vancomycin	2011
Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). International journal of antimicrobial agents, 2011, Volume: 37, Issue:6 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Humans; Linezolid; Lipoglycopeptides; Microbial Sensitivity Tests; Microbial Viability; Oxazolidinones; Staphylococcal Infections; Staphylococcus aureus; Time Factors; Vancomycin; Vancomycin Resistance	2011
On a different level: telavancin versus vancomycin for hospital-acquired pneumonia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 52, Issue:11 Topics: Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Pneumonia, Bacterial; Treatment Outcome; Vancomycin	2011
Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:11 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Daptomycin; Humans; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Minocycline; Osteomyelitis; Oxazolidinones; Staphylococcal Infections; Tigecycline; Vancomycin	2011
Detection of vancomycin levels in patients receiving telavancin but not vancomycin. The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:2 Topics: Aminoglycosides; Anti-Bacterial Agents; Humans; Lipoglycopeptides; Serum; Vancomycin	2012
Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2 Topics: Aminoglycosides; Anti-Bacterial Agents; Colony Count, Microbial; Daptomycin; Drug Resistance, Bacterial; Endocarditis, Bacterial; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Biological; Staphylococcus aureus; Vancomycin	2012
Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin. Scandinavian journal of infectious diseases, 2012, Volume: 44, Issue:8 Topics: Aminoglycosides; Analysis of Variance; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Colony Count, Microbial; Daptomycin; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Vancomycin	2012
Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8 Topics: Aminoacyltransferases; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Daptomycin; DNA-Binding Proteins; Drug Tolerance; Gene Expression Regulation, Bacterial; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Vancomycin; Vancomycin Resistance	2012
Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, Aug-15, Volume: 69, Issue:16 Topics: Aminoglycosides; Anti-Bacterial Agents; Anticoagulants; Catheter-Related Infections; Catheterization, Central Venous; Citrates; Drug Combinations; Drug Incompatibility; Drug Stability; Heparin; Humans; Infusions, Intravenous; Isotonic Solutions; Lipoglycopeptides; Sodium Citrate; Thrombosis; Time Factors; Vancomycin	2012
Transplacental transfer of vancomycin and telavancin. American journal of obstetrics and gynecology, 2012, Volume: 207, Issue:4 Topics: Aminoglycosides; Anti-Bacterial Agents; Female; Humans; Lipoglycopeptides; Maternal-Fetal Exchange; Perfusion; Placenta; Pregnancy; Vancomycin	2012
Can a vancomycin assay be utilised to predict plasma telavancin concentrations? International journal of antimicrobial agents, 2013, Volume: 41, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Humans; Lipoglycopeptides; Plasma; Vancomycin	2013
Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant. Microbial drug resistance (Larchmont, N.Y.), 2013, Volume: 19, Issue:4 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Cell Membrane; Cell Wall; Daptomycin; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Lipoglycopeptides; Membrane Fluidity; Microbial Sensitivity Tests; Staphylococcus aureus; Transcriptome; Vancomycin; Vancomycin Resistance	2013
Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2013, Volume: 32, Issue:10 Topics: Aminoglycosides; Anti-Bacterial Agents; Biofilms; Drug Resistance, Multiple, Bacterial; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Microbial Viability; Staphylococcal Infections; Staphylococcus aureus; Vancomycin	2013
Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. International journal of antimicrobial agents, 2013, Volume: 42, Issue:4 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Cross Infection; Humans; Lipoglycopeptides; Pneumonia, Bacterial; Treatment Outcome; Vancomycin	2013
Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia. Transplant infectious disease : an official journal of the Transplantation Society, 2013, Volume: 15, Issue:5 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Debridement; Defibrillators, Implantable; Female; Heart Transplantation; Heart-Assist Devices; Humans; Lipoglycopeptides; Mediastinitis; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin; Vancomycin Resistance	2013
Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Ciprofloxacin; Colistin; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Fosfomycin; In Vitro Techniques; Klebsiella pneumoniae; Lipoglycopeptides; Meropenem; Microbial Sensitivity Tests; Minocycline; Rifampin; Thienamycins; Tigecycline; Vancomycin	2014
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Female; Humans; Lipoglycopeptides; Male; Middle Aged; Pneumonia; Staphylococcus aureus; United States; Vancomycin	2014
Which antibiotic for hospital acquired pneumonia caused by MRSA? BMJ (Clinical research ed.), 2014, Feb-13, Volume: 348 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Cross Infection; Daptomycin; Humans; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Minocycline; Oxazolidinones; Pneumonia, Staphylococcal; Tigecycline; Vancomycin; Virginiamycin	2014
Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties. Carbohydrate research, 2014, May-07, Volume: 389 Topics: Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Bacillus subtilis; Carbohydrate Conformation; Glycopeptides; Lipoglycopeptides; Molecular Dynamics Simulation; Peptidoglycan; Staphylococcus aureus; Vancomycin	2014
In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients. The Journal of antibiotics, 2014, Volume: 67, Issue:7 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Linezolid; Lipoglycopeptides; Microbial Sensitivity Tests; Neoplasms; Oxazolidinones; Vancomycin	2014
Variability in telavancin cross-reactivity among vancomycin immunoassays. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:12 Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies; Artifacts; Biotransformation; Cross Reactions; Gram-Positive Bacteria; Humans; Immunoassay; Lipoglycopeptides; Reproducibility of Results; Sensitivity and Specificity; Vancomycin	2014
Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Daptomycin; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; United States; Vancomycin	2015
Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin. Journal of clinical microbiology, 2015, Volume: 53, Issue:8 Topics: Aminoglycosides; Anti-Bacterial Agents; Diagnostic Errors; Enterococcus faecalis; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus; Vancomycin	2015
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10 Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Female; Humans; Lipoglycopeptides; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Skin Diseases, Infectious; Vancomycin	2015
In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Area Under Curve; Cell Culture Techniques; Colony Count, Microbial; Humans; Lipoglycopeptides; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Statistical; Vancomycin	2016
Telavancin (Vibativ). A vancomycin derivative, no more effective but more toxic. Prescrire international, 2015, Volume: 24, Issue:165 Topics: Aminoglycosides; Anti-Bacterial Agents; Humans; Lipoglycopeptides; Pneumonia, Bacterial; Vancomycin	2015
Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. Antimicrobial agents and chemotherapy, 2015, Dec-28, Volume: 60, Issue:3 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Daptomycin; Host-Pathogen Interactions; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moths; RNA, Bacterial; Staphylococcal Infections; Vancomycin; Vancomycin Resistance	2015
Comparison of telavancin and vancomycin lock solutions in eradication of biofilm-producing staphylococci and enterococci from central venous catheters. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Mar-01, Volume: 73, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Biofilms; Catheter-Related Infections; Central Venous Catheters; Enterococcus; Humans; Lipoglycopeptides; Pharmaceutical Solutions; Staphylococcus; Staphylococcus aureus; Staphylococcus epidermidis; Vancomycin	2016
Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:10 Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Daptomycin; Disease Models, Animal; Endocarditis, Bacterial; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Rabbits; Staphylococcal Infections; Vancomycin	2016
Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients. Diagnostic microbiology and infectious disease, 2017, Volume: 87, Issue:4 Topics: Aminoglycosides; Anti-Bacterial Agents; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Neoplasms; Staphylococcal Infections; Time Factors; Vancomycin	2017
In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci. Diagnostic microbiology and infectious disease, 2017, Volume: 89, Issue:2 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Carbon-Oxygen Ligases; Daptomycin; Drug Resistance, Multiple, Bacterial; Enterococcus faecalis; Enterococcus faecium; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Teicoplanin; Vancomycin; Vancomycin Resistance	2017
Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus. Clinical therapeutics, 2018, Volume: 40, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Antimicrobial Stewardship; Cost-Benefit Analysis; Cross Infection; Drug Costs; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Staphylococcal; Staphylococcus aureus; Vancomycin	2018
Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials. Pharmacotherapy, 2018, Volume: 38, Issue:10 Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Creatinine; Female; Healthcare-Associated Pneumonia; Humans; Kidney Function Tests; Lipoglycopeptides; Male; Middle Aged; Pneumonia, Staphylococcal; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Vancomycin	2018
Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2018, Volume: 17, Issue:6 Topics: Adolescent; Aminoglycosides; Anti-Bacterial Agents; Child; Cross Infection; Cystic Fibrosis; Drug Hypersensitivity; Female; Humans; Lipoglycopeptides; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections; Treatment Outcome; Vancomycin	2018
Impact of different pathophysiological conditions on antimicrobial activity of glycopeptides in vitro. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2019, Volume: 25, Issue:6 Topics: Albumins; Aminoglycosides; Anti-Infective Agents; Glycopeptides; Humans; Hydrogen-Ion Concentration; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Teicoplanin; Temperature; Vancomycin	2019
Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Calcium; Ciprofloxacin; Colistin; Culture Media; Depsipeptides; Escherichia coli; Factor Analysis, Statistical; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxacillin; Penicillin G; Plastics; Polymyxin B; Polysorbates; Rifampin; Teicoplanin; Trimethoprim; Vancomycin	2019
Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019, Volume: 38, Issue:12 Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Daptomycin; Drug Tolerance; Female; Humans; Lipoglycopeptides; Male; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Staphylococcal Infections; Staphylococcus aureus; Tertiary Care Centers; Vancomycin; Young Adult	2019
Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype. The Journal of allergy and clinical immunology, 2021, Volume: 147, Issue:1 Topics: Aminoglycosides; Drug Hypersensitivity Syndrome; Haplotypes; HLA-A Antigens; Humans; Lipoglycopeptides; Teicoplanin; Vancomycin	2021
Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resist International journal of antimicrobial agents, 2021, Volume: 58, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Daptomycin; Drug Resistance, Bacterial; Enterococcus faecium; Epidemiological Monitoring; Gram-Positive Bacterial Infections; Humans; Linezolid; Lipoglycopeptides; Microbial Sensitivity Tests; Oxazolidinones; Taiwan; Tetracyclines; Tetrazoles; Tigecycline; Vancomycin; Vancomycin-Resistant Enterococci; Virginiamycin	2021